Cipla is heavily leveraging digitalization, focusing on new markets

8 Aug 2022 , 07:45 AM

To fuel its next phase of expansion, pharmaceutical giant Cipla is placing a significant bet on digitalization and burgeoning markets like biosimilars and mRNA-assisted medicines. The Mumbai-based pharmaceutical company is likewise optimistic about maximizing the value opportunity in the US market’s complex generics.

While keeping an eye on anticipated complicated product launches in the second half of the current fiscal year, it is also trying to ramp up its US core formulations sales on the strength of respiratory and peptide businesses.

Samina Hamied, the executive vice-chairperson of Cipla, stated in the company’s annual report for 2021—22, “Digitalization in healthcare found its rightful place during the pandemic, and there is a need to expand and support the essential backup services to enable digital healthcare to function efficiently in all primary and secondary healthcare centers.”

The pharmaceutical company has started to digitally change every aspect of the value chain, including finance, R&D, manufacturing, supply chain, human resources, customer service, and stakeholder engagement, she continued.

In recent years, the company has established a number of key pillars to support its digitization and automation objectives, from adopting cutting-edge trends to transforming patient reach and customer service through digitalization, according to Hamied.

Umang Vohra, the managing director and global chief executive officer of Cipla, stated that going forward, “our digital transformation activities will feed all our growth engines.”

He went on to say that it would be crucial to keep an eye out for healthcare innovations that are causing a paradigm change, such as mRNA technology, DNA subunit vaccinations, or technology involving certain antibodies and cancer reversal.

He said the business is committed to creating a powerful global wellness franchise and is looking for other brands in South Africa and India with significant market potential.

The third-largest pharmaceutical company in the nation, Cipla, has 47 manufacturing facilities worldwide that serve 86 markets.